@entity6740 , XXXX and 17-beta-estradiol levels during extra-amniotically induced @entity5852 by a new prostaglandin derivative (Sulprostone).

@entity1 @entity5852 @entity1420 @entity1421 @entity294 @entity6740 @entity2918 @entity6002 @entity158 @entity10769
A new @entity1421 derivative ( @entity6002 ) was given extra-amniotically to 17 healthy @entity1 , who were 7-8 weeks pregnant, in order to assess the plasma profile of @entity6740 , 17 @entity10769 (E2), and @entity1420 and to evaluate the effectiveness and overall acceptability of the method in relation to different dose levels. On the lowest dose level (5 micrograms) only 3 of 7 @entity1 aborted within a 3-to 6-day period. At higher dose levels (10 and 15 micrograms, respectively) 9 out of 10 @entity1 exhibited clinical evidence of an abortion. In the group who aborted, E2, @entity1420 , and @entity6740 decreased continuously, whereas in the nonabortion group decreased levels were found 3 and 6 h after administration of the drug, but already after 24 h the values had again increased. Practically all treated @entity1 experienced lower abdominal discomfort, 7 (41%) reported the @entity158 being severe. Vomiting and/or @entity294 occurred in 4 @entity1 (24%). Similarly to other hitherto tested @entity2918 in @entity1 , this new analogue exhibits its effect primarily through direct stimulatory effect on the uterine smooth muscle, resulting in subsequent decline in the concentrations of @entity6740 , E2, and @entity1420 . In the group of successful inductions the decrease of the @entity6740 concentration was close the half-time of @entity6740 , indicating a permanent damage to the placenta. Despite the high success rate at a dose of 10 micrograms or more, the side effects, mainly abdominal cramps. were too severe to make this method feasible for the induction of @entity5852 when comparing to the available routine procedure of rapid vacuum curettage used on an outpatients basis.
